These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 12456069)
21. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Doody RS; Gavrilova SI; Sano M; Thomas RG; Aisen PS; Bachurin SO; Seely L; Hung D; Lancet; 2008 Jul; 372(9634):207-15. PubMed ID: 18640457 [TBL] [Abstract][Full Text] [Related]
27. Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer's Disease Suggest Disease Modification Potential. Abushakra S; Porsteinsson A; Scheltens P; Sadowsky C; Vellas B; Cummings J; Gauthier S; Hey JA; Power A; Wang P; Shen L; Tolar M J Prev Alzheimers Dis; 2017; 4(3):149-156. PubMed ID: 29182706 [TBL] [Abstract][Full Text] [Related]
28. Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study. Florian H; Meier A; Gauthier S; Lipschitz S; Lin Y; Tang Q; Othman AA; Robieson WZ; Gault LM J Alzheimers Dis; 2016; 51(4):1237-47. PubMed ID: 26967214 [TBL] [Abstract][Full Text] [Related]
29. Response patterns of EGb 761 in Alzheimer's disease: influence of neuropsychological profiles. Le Bars PL Pharmacopsychiatry; 2003 Jun; 36 Suppl 1():S50-5. PubMed ID: 13130389 [TBL] [Abstract][Full Text] [Related]
30. Management of patients with Alzheimer's disease plus cerebrovascular disease: 12-month treatment with galantamine. Bullock R; Erkinjuntti T; Lilienfeld S; Dement Geriatr Cogn Disord; 2004; 17(1-2):29-34. PubMed ID: 14560062 [TBL] [Abstract][Full Text] [Related]
31. Extended-release physostigmine in Alzheimer disease: a multicenter, double-blind, 12-week study with dose enrichment. Physostigmine Study Group. van Dyck CH; Newhouse P; Falk WE; Mattes JA Arch Gen Psychiatry; 2000 Feb; 57(2):157-64. PubMed ID: 10665618 [TBL] [Abstract][Full Text] [Related]
32. Velnacrine for the treatment of Alzheimer's disease: a double-blind, placebo-controlled trial. The Mentane Study Group. Zemlan FP J Neural Transm (Vienna); 1996; 103(8-9):1105-16. PubMed ID: 9013398 [TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of donepezil in patients with Alzheimer's disease: results of a global, multinational, clinical experience study. Boada-Rovira M; Brodaty H; Cras P; Baloyannis S; Emre M; Zhang R; Bahra R; Drugs Aging; 2004; 21(1):43-53. PubMed ID: 14715043 [TBL] [Abstract][Full Text] [Related]
34. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Black SE; Doody R; Li H; McRae T; Jambor KM; Xu Y; Sun Y; Perdomo CA; Richardson S Neurology; 2007 Jul; 69(5):459-69. PubMed ID: 17664405 [TBL] [Abstract][Full Text] [Related]
35. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial. Farlow M; Potkin S; Koumaras B; Veach J; Mirski D Arch Neurol; 2003 Jun; 60(6):843-8. PubMed ID: 12810489 [TBL] [Abstract][Full Text] [Related]
37. Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials. Atri A; Frölich L; Ballard C; Tariot PN; Molinuevo JL; Boneva N; Windfeld K; Raket LL; Cummings JL JAMA; 2018 Jan; 319(2):130-142. PubMed ID: 29318278 [TBL] [Abstract][Full Text] [Related]
38. Assessing therapeutic efficacy in a progressive disease: a study of donepezil in Alzheimer's disease. Johannsen P; Salmon E; Hampel H; Xu Y; Richardson S; Qvitzau S; Schindler R; CNS Drugs; 2006; 20(4):311-25. PubMed ID: 16599649 [TBL] [Abstract][Full Text] [Related]
39. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group. Homma A; Takeda M; Imai Y; Udaka F; Hasegawa K; Kameyama M; Nishimura T Dement Geriatr Cogn Disord; 2000; 11(6):299-313. PubMed ID: 11044775 [TBL] [Abstract][Full Text] [Related]
40. Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomised, placebo-controlled, double-blind trial. Burns A; Bernabei R; Bullock R; Cruz Jentoft AJ; Frölich L; Hock C; Raivio M; Triau E; Vandewoude M; Wimo A; Came E; Van Baelen B; Hammond GL; van Oene JC; Schwalen S Lancet Neurol; 2009 Jan; 8(1):39-47. PubMed ID: 19042161 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]